3.81  -0.13 (-3.3%)		01-21 16:00
Open: 3.86 High: 3.98 Volume: 358,347		Pre. Close: 3.94 Low: 3.7 Market Cap: 279(M)

Short term
Mid term
Targets	6-month :	5.2	1-year :	5.82
Resists	First :	4.45	Second :	4.98
Pivot price	4.15
Supports	First :	3.58	Second :	2.98
MAs	MA(5) :	3.82	MA(20) :	4.24
	MA(100) :	3.03	MA(250) :	1.5
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	15.5	D(3) :	10.8
RSI	RSI(14): 42.7
52-week	High :	5.11	Low :	0.23

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RLMD ] has closed above bottom band by 20.9%. Bollinger Bands are 13.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.99 - 4.01	4.01 - 4.03
Low:	3.63 - 3.66	3.66 - 3.69
Close:	3.77 - 3.81	3.81 - 3.85

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Mon, 12 Jan 2026
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network

Mon, 12 Jan 2026
FDA backs new bladder cancer studies for patients with few options left - Stock Titan

Mon, 22 Dec 2025
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq

Tue, 16 Dec 2025
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus

Mon, 15 Dec 2025
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com

Wed, 03 Dec 2025
Relmada Therapeutics (RLMD) reports 9-month 92% CR for NDV-01 in NMIBC, eyes Phase 3 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	73 (M)
Shares Float	65 (M)
Held by Insiders	10.7 (%)
Held by Institutions	18.6 (%)
Shares Short	1,390 (K)
Shares Short P.Month	773 (K)

EPS	-1.78
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-102.5 %
Return on Equity (ttm)	-196.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-2.15
PEG Ratio	0
Price to Book value	13.6
Price to Sales	0
Price to Cash Flow	-6.99

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.